INBX
Inhibrx Biosciences Inc.Healthcare · $1.5B market cap
Verdict
We can't put a fair value on INBX right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow INBX
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds INBX. In Q2 2026, 1 trimmed. Who we track
Moves in Q2 2026
Trimmed: Viking Global Investors
Insider activity
Since Sep 8, 2026: 8 open-market purchases worth $3.5M and 2 sales worth $115K. Why purchases matter
Purchases
Lappe Mark
Chief Executive Officer · 2026-09-08
Bought
$1.1M
Lappe Mark
Chief Executive Officer · 2026-09-08
Bought
$136K
Lappe Mark
Chief Executive Officer · 2026-09-08
Bought
$54K
Lappe Mark
Chief Executive Officer · 2026-09-08
Bought
$118K
Lappe Mark
Chief Executive Officer · 2026-09-08
Bought
$665K
Lappe Mark
Chief Executive Officer · 2026-09-08
Bought
$585K
FORSYTH DOUGLAS
director · 2026-09-08
Bought
$287K
Kayyem Jon Faiz
director · 2026-09-08
Bought
$568K
Sales
About Inhibrx Biosciences Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works